



ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials

*Partnership advances the production and delivery of
 ^{212}Pb -based therapies through ARTBIO's proprietary
AlphaDirect™ isolation technology*

*Agreement signifies important milestone as Nucleus
RadioPharma's first commercial partnership*

**CAMBRIDGE, Mass. and ROCHESTER, Minn. —
May 7, 2024** — ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), and Nucleus RadioPharma Inc. (Nucleus), the world's first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced a strategic manufacturing and supply agreement to support ARTBIO's therapeutic product manufacturing.





program in prostate cancer, AB001, using ARTBIO'S proprietary AlphaDirect™ ^{212}Pb isolation technology. This agreement will enable the supply and manufacturing of ARTs from Nucleus' facility in Rochester, Minn., for patients living in the Northern and Midwest U.S.

"As we continue building our distributed manufacturing capabilities in the U.S. and globally, selecting partners who share our patient-centric vision is critical," said Emanuele Ostuni, Ph.D., Chief Executive Officer of ARTBIO. "The Nucleus team shares our passion to make targeted radiopharmaceutical therapies accessible, and together, we commit to bringing a new class of alpha radioligand therapies to hospitals across greater Minnesota and beyond."

"This strategic partnership with ARTBIO underscores our unwavering commitment to transforming the lives of cancer patients through groundbreaking therapies," said Charles S. Conroy, Chief Executive Officer of Nucleus. "We are thrilled to unite in our mission to address the pressing need for innovative radiopharmaceuticals, ensuring that patients have access to potentially life-changing treatments with highest quality and supply chain resilience."

AlphaDirect™ is a first-of-its-kind system that delivers highly pure ^{212}Pb from widely available raw materials. ^{212}Pb is an alpha-emitting radioisotope that has gained attention for its potential applications in therapeutic medicine, particularly in targeted

DH-1



with ^{212}Pb have been promising, indicating that ^{212}Pb has the potential to address unmet clinical needs.

About ARTBIO

ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (^{212}Pb) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect™ technology, a first-of-its-kind ^{212}Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs.

ARTBIO is advancing multiple pipeline programs with lead program AB001 currently in first in human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway's Radium Hospital. For more information, visit www.artbio.com, and follow us on **LinkedIn** and **Twitter**.

About Nucleus RadioPharma

Nucleus RadioPharma is an innovative CDMO in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, the company provides an array of services, from formulation and analytical development to regulatory documentation and drug product



through clinical trials to commercialization.
Recognized for its flexible approach, the company offers multiple onboarding points to accommodate innovators at various stages of their product lifecycle. Please visit **nucleusrad.com** and follow on **LinkedIn** for more information.

© 2025 ARTBIO | All rights reserved.

Contact

Terms of Service

Privacy Policy

Clinical Trials

Locations

U.S.	Switzerland	Norway	UK	UK
(Headquarters)	ARTBIO	ARTBIO	(Outreach	(Office)
ARTBIO	GmbH	AS	&	ARTBIO
Inc.	Aeschengraben	Oslo	Shipments)	Limited
c/o	9	Science	ARTBIO	The
Alexandria	4051	Park,	Limited	Harley
LaunchLabs	Basel,	Gaustadalléen	3rd Floor,	Building
One	Switzerland	21	1 Ashley	77 New
Kendall		0349	Road	Cavendish
Sq, B200,		Oslo,	Altrincham,	St
Suite 001		Norway	Cheshire	London

21/10/2025, 00:26

ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing R...

DH-1

